A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)



Status:Active, not recruiting
Conditions:Breast Cancer, Lung Cancer, Prostate Cancer, Skin Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:10/19/2018
Start Date:December 2014
End Date:June 2019

Use our guide to learn which trials are right for you!

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

The purpose of this study is to explore the safety, tolerability, pharmacokinetics,
immunogenicity and preliminary efficacy of INCB024360 administered in combination with
MEDI4736 in subjects with selected advanced solid tumors.


Inclusion Criteria:

- Male or female subjects, age 18 years or older

- Histologically or cytologically confirmed diagnosis of selected locally advanced or
metastatic solid tumors

- Must have failed at least 1 prior treatment regimen for locally advanced or metastatic
disease or be intolerant to treatment or refuse standard treatment

Exclusion Criteria:

- Laboratory and medical history parameters not within protocol-defined range

- Participation in any other study in which receipt of an investigational study drug
occurred within 28 days or 5 half-lives (whichever is longer) prior to first dose

- Prior treatment with immune checkpoint inhibitors (eg, anti-CTLA-4, anti-PD-1,
anti-PD-L1, and any other antibody or drug specifically targeting T-cell
co-stimulation) or an IDO inhibitor (exception is tumor types in which a PD-1 pathway
targeted agent is approved, e.g. melanoma, non-small cell lung cancer.)

- Receipt of any anticancer medication in the 21 days prior to receiving the first dose
of study medication

- Has an active or inactive autoimmune process

- Evidence of interstitial lung disease or active, non-infectious pneumonitis

- Prior radiotherapy within 2 weeks of initiating treatment; Must have recovered from
all radiation-related toxicities, not require corticosteroids, and not have had
radiation pneumonitis

- Untreated central nervous system (CNS) metastases or CNS metastases that have
progressed

- Currently pregnant or breastfeeding
We found this trial at
13
sites
?
mi
from
Port Saint Lucie, FL
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Denver, CO
Click here to add this to my saved trials
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
Huntersville, North Carolina 28078
?
mi
from
Huntersville, NC
Click here to add this to my saved trials
?
mi
from
Louisville, KY
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
?
mi
from
Sarasota, FL
Click here to add this to my saved trials
?
mi
from
Tampa, FL
Click here to add this to my saved trials
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials